UnknownNot Applicable

Efficacy and Safety of Cilostazol in Patients of Vascular Cognitive Impairment-no Dementia (VCIND)

China200 participantsStarted 2010-11

Plain-language summary

Patients of vascular cognitive impairment-no dementia (VCIND) in one group is prescribed cilostazol,in the other group is prescribed aspirin. Evaluate both of them in cognitive function, MRI and other sides at given time. The investigators hypothesize that cilostazol is more efficient and safer than aspirin in patients with VCIND.

Who can participate

Age range50 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Aged between 50-80, both gender；
✓. Small vessel disease and associated cognitive impairment, diagnosed as VCIND；
✓. Non-specific subjective symptoms (dizziness, somnolence, numbness in limbs) are acceptable.
✓. Normal hepatic and renal function.
✓. With good compliance.

Exclusion criteria

✕. Aged above 80 or less than 50.
✕. Dementia.
✕. Cerebral infarction(\>2cm).
✕. Major vascular lesion. (stenosis\>50%).
✕. Cardiac cerebral infarction.
✕. Intracerebral Hemorrhage.
✕. Clinical manifestations cannot attribute to small vessel disease.
✕. Major depression or dysfunction in speech, visual ability, hearing or aphasia that would interfere with the cognitive assessment.

What they're measuring

changes in cognitive function

Timeframe: baseline, 3month, 6month, 1year, and 2year

Trial details

NCT IDNCT01872858

SponsorHuashan Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-11

View on ClinicalTrials.gov More Mild Cognitive Impairment trials